Overview
Papillon-Lefèvre syndrome (PLS) is an autosomal-recessive genodermatosis characterized by severe palmoplantar keratoderma and aggressive, early-onset periodontitis. This rare condition, affecting approximately 1 to 4 individuals per million, is primarily driven by mutations in the cathepsin C gene (CTSC), which impair the function of cathepsin C, a critical cysteine protease involved in the activation of several immune-related proteins. The resultant immunodeficiency leads to compromised host defense mechanisms, particularly against periodontal pathogens, resulting in rapid and extensive tooth loss in childhood. PLS often presents in early childhood, with cutaneous manifestations typically appearing between 6 months and 4 years of age, alongside aggressive periodontal disease affecting both primary and permanent dentition. Understanding the genetic, clinical, and therapeutic aspects of PLS is crucial for early diagnosis and effective management to mitigate its debilitating effects on oral health and quality of life.
Pathophysiology
Papillon-Lefèvre syndrome arises from mutations in the cathepsin C gene (CTSC), leading to reduced or inactive cathepsin C activity. This enzyme plays a pivotal role in the activation of neutrophil elastase and cathepsin G, essential components of the innate immune response. The deficiency in cathepsin C function impairs the maturation and activation of these proteases, thereby compromising the host's ability to combat bacterial infections effectively [PMID:34513733]. Consequently, patients exhibit heightened susceptibility to periodontal pathogens, particularly Aggregatibacter actinomycetemcomitans, which form robust biofilms resistant to clearance [PMID:38297252]. This compromised immune defense contributes significantly to the rapid progression of periodontitis, characterized by severe gingival inflammation, bone loss, and premature tooth loss [PMID:22922917].
Mutations in CTSC manifest as various types, including missense, nonsense, and splice variants, each potentially influencing the severity and clinical presentation of PLS [PMID:36058494]. For instance, a novel seven-base deletion (c.681delCATACAT) leading to a frameshift mutation and premature stop codon has been identified, underscoring the diverse genetic underpinnings of the syndrome [PMID:23397598]. Despite the identification of numerous CTSC mutations, the observed phenotypic heterogeneity suggests that additional genetic or environmental factors may modulate disease severity [PMID:18294227]. Furthermore, impaired natural killer (NK) cell cytotoxicity, consistently observed in PLS patients, further elucidates the broader immune dysfunction contributing to the aggressive periodontitis seen in these individuals [PMID:15840775]. Elevated levels of inflammatory cytokines such as IL-1beta and matrix metalloproteinases (MMP-8) in gingival crevicular fluid (GCF) provide biochemical markers of the heightened inflammatory response characteristic of PLS [PMID:15198385].
Epidemiology
Papillon-Lefèvre syndrome has a low prevalence, affecting approximately 1 to 4 individuals per million globally. The condition exhibits a strong association with consanguineous marriages, where the risk of offspring inheriting the recessive mutation is significantly increased due to the higher likelihood of both parents being carriers [PMID:34513733]. This genetic predisposition is further highlighted by familial clustering cases, such as the rare occurrence in three siblings, emphasizing the importance of genetic counseling in families with a history of consanguinity [PMID:28091448]. Although consanguinity is a notable risk factor, the presence of homozygous mutations in affected individuals suggests that genetic relatedness among parents, even without consanguinity, can still lead to the manifestation of PLS [PMID:23397598]. Understanding these epidemiological factors is crucial for early identification and intervention in high-risk populations.
Clinical Presentation
The clinical presentation of Papillon-Lefèvre syndrome typically manifests between 6 months and 4 years of age, with characteristic cutaneous and periodontal features. Cutaneous manifestations include diffuse palmoplantar hyperkeratosis, often accompanied by erythema and scaling, which can extend to other areas such as the elbows and knees [PMID:38297252]. These skin lesions are often the earliest signs of the syndrome and can vary in severity, correlating with specific CTSC protein activation profiles in urine [PMID:36058494]. Concurrently, aggressive periodontitis emerges, characterized by rapid gingival inflammation, significant bone loss, and premature tooth mobility and loss affecting both primary and permanent dentition [PMID:22922917]. This periodontal disease often becomes clinically apparent during dental exfoliation, leading to substantial tooth loss by early childhood, significantly impacting the patient's quality of life [PMID:40000042].
Additional clinical features include craniofacial anomalies, such as a Class III skeletal pattern, characterized by retrognathia, decreased lower facial height, and retroclined mandibular incisors, as observed in cephalometric analyses [PMID:18617113]. These skeletal changes highlight the multifaceted impact of PLS beyond oral health, influencing overall facial structure and potentially requiring multidisciplinary management approaches. The variability in clinical presentations underscores the need for comprehensive evaluation, including both dermatological and periodontal assessments, to ensure accurate diagnosis and tailored management strategies [PMID:18294227].
Diagnosis
Diagnosis of Papillon-Lefèvre syndrome relies heavily on clinical criteria, particularly the presence of diffuse palmoplantar keratoderma and severe periodontitis in early childhood. However, genetic testing plays a pivotal role in confirming the diagnosis. Direct sequencing of the CTSC gene can identify specific mutations, such as the novel seven-base deletion (c.681delCATACAT) leading to a frameshift mutation, which has been confirmed in affected families [PMID:23397598]. Additionally, urinary profiles of CTSC protein activation products, including dimeric and monomeric forms, can differentiate PLS patients from controls and correlate with disease severity [PMID:36058494]. Genetic analysis not only aids in diagnosis but also helps in identifying heterozygous carriers within families, crucial for genetic counseling [PMID:15857086].
Immunological assessments, such as measuring NK cell cytotoxicity and inflammatory markers like IL-1beta and MMP-8 in GCF, can provide supportive evidence for diagnosis and monitor disease activity [PMID:15840775, PMID:15198385]. These biomarkers offer potential for distinguishing between active and non-active disease states, guiding therapeutic interventions. Early diagnosis is critical, as delayed identification can lead to advanced periodontitis and significant tooth loss, as highlighted in case reports where initial symptoms were overlooked [PMID:40000042]. Therefore, a multidisciplinary approach combining clinical evaluation, genetic testing, and biochemical markers is essential for accurate and timely diagnosis of PLS.
Differential Diagnosis
Differentiating Papillon-Lefèvre syndrome from other conditions with similar presentations requires careful clinical and laboratory evaluation. Conditions such as hereditary palmoplantar keratodermas (e.g., Vohwinkel syndrome, tylosis) and other forms of early-onset periodontitis (e.g., chronic juvenile periodontitis) must be considered. Hereditary palmoplantar keratodermas often lack the severe periodontal component seen in PLS, though some overlap in cutaneous manifestations can occur. Early-onset periodontitis, particularly in the absence of genetic mutations, may present with aggressive periodontal destruction but typically lacks the characteristic skin lesions of PLS. Genetic testing for CTSC mutations is crucial in distinguishing PLS from these conditions, as it provides definitive evidence of the underlying molecular defect [PMID:18294227]. Additionally, assessing NK cell function and specific inflammatory markers like IL-1beta and MMP-8 can further refine the differential diagnosis, highlighting the multifaceted nature of PLS pathophysiology.
Management
Effective management of Papillon-Lefèvre syndrome focuses on mitigating the aggressive periodontal disease and addressing associated complications. Given the rapid progression of periodontitis, aggressive dental interventions are essential. These include thorough oral hygiene education, professional periodontal debridement, and regular supportive periodontal therapy to slow disease progression [PMID:22922917]. Antibiotics may be employed to control acute exacerbations, particularly when there is significant infection or inflammation [PMID:34513733]. In cases where extensive tooth loss has occurred, prosthetic rehabilitation, such as conventional complete dentures, can significantly improve quality of life [PMID:40000042].
Understanding the genetic heterogeneity of PLS suggests that management strategies should consider individual mutation profiles to optimize outcomes [PMID:18294227]. Monitoring urinary CTSC profiles and inflammatory markers like IL-1beta can help tailor interventions and assess disease progression [PMID:36058494, PMID:15198385]. Emerging therapeutic targets include enhancing innate immune function, such as exploring immunomodulatory interventions to boost NK cell cytotoxicity and neutrophil function [PMID:15840775]. Additionally, leveraging antimicrobial peptides like LL-37, which can disrupt bacterial biofilms, offers potential future therapeutic avenues [PMID:38297252]. Regular follow-up and proactive dental care are crucial to manage disease progression effectively and maintain oral health as long as possible [PMID:28091448].
Complications
Patients with Papillon-Lefèvre syndrome face significant complications beyond the primary manifestations of palmoplantar keratoderma and periodontitis. The compromised immune function, particularly the impaired neutrophil chemotaxis and reduced NK cell cytotoxicity, predisposes individuals to recurrent and severe infections, both oral and cutaneous [PMID:34513733]. These infections can exacerbate periodontal disease and complicate wound healing, further compromising oral health and overall well-being. Additionally, the aggressive nature of periodontitis can lead to significant craniofacial deformities, such as alveolar bone loss and tooth loss, affecting facial structure and function [PMID:18617113]. Nutritional deficiencies often arise due to difficulties in eating secondary to painful oral conditions, impacting growth and development, especially in pediatric patients [PMID:34513733]. These multifaceted complications underscore the need for comprehensive, multidisciplinary care to address both immediate and long-term health issues.
Prognosis & Follow-up
The prognosis for patients with Papillon-Lefèvre syndrome is generally guarded due to the relentless progression of periodontal disease, which typically results in significant tooth loss by early adolescence [PMID:40000042]. However, proactive dental management strategies, including regular periodontal debridement, supportive therapy, and meticulous oral hygiene practices, can help preserve remaining teeth and delay disease progression [PMID:28091448]. Regular follow-up appointments are essential to monitor disease activity, adjust treatment plans, and manage complications effectively. Biomarkers such as IL-1beta levels in GCF can serve as indicators of disease activity, guiding therapeutic interventions [PMID:15198385]. Despite these efforts, the overall prognosis often involves lifelong management of skin and oral health issues, with a focus on maintaining function and quality of life through advanced prosthodontic solutions and supportive care.
Key Recommendations
These recommendations aim to provide a structured approach to managing PLS, emphasizing early intervention, comprehensive care, and personalized treatment strategies to improve patient outcomes.
References
1 Vályi P, Wirth R, Minárovits J, Strang O, Maróti G, Kovács KL. The oral microbiome of a family including Papillon-Lefèvre-syndrome patients and clinically healthy members. BMC oral health 2024. link 2 Lettieri GM, Santiago LM, Lettieri GC, Borges LGDA, Marconatto L, de Oliveira LA et al.. Oral Phenotype and Salivary Microbiome of Individuals With Papillon-Lefèvre Syndrome. Frontiers in cellular and infection microbiology 2021. link 3 Singh AP, Chaitra TR, Singh SP, Kulkarni AU. Initial expression of the Papillon-Lefevre syndrome in consanguine family. BMJ case reports 2012. link 4 Syed FA, Arshad H, Batool I, Khalid T. Dental management of a young patient with Papillon-Lefèvre syndrome. BMJ case reports 2025. link 5 Sabry S, Abouzaid MR, Mostafa MI, Abdel-Hamid MS, Saad AK, Soliman HN et al.. Abnormal profiles of cathepsin C secreted in urine of Papillon Lefevre syndrome patients. European journal of medical genetics 2022. link 6 Gungor OE, Karayilmaz H, Yalcin H, Hatipoğlu M. Oro-dental characteristics of three siblings with Papillon-Lefevre syndrome. Nigerian journal of clinical practice 2017. link 7 Farkas K, Paschali E, Papp F, Vályi P, Széll M, Kemény L et al.. A novel seven-base deletion of the CTSC gene identified in a Hungarian family with Papillon-Lefèvre syndrome. Archives of dermatological research 2013. link 8 Bindayel NA, Ullbro C, Suri L, Al-Farra E. Cephalometric findings in patients with Papillon-Lefèvre syndrome. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 2008. link 9 Noack B, Görgens H, Schacher B, Puklo M, Eickholz P, Hoffmann T et al.. Functional Cathepsin C mutations cause different Papillon-Lefèvre syndrome phenotypes. Journal of clinical periodontology 2008. link 10 Nitta H, Wara-Aswapati N, Lertsirivorakul J, Nakamura T, Yamamoto M, Izumi Y et al.. A novel mutation of the cathepsin C gene in a thai family with Papillon-Lefevre syndrome. Journal of periodontology 2005. link 11 Lundgren T, Parhar RS, Renvert S, Tatakis DN. Impaired cytotoxicity in Papillon-Lefèvre syndrome. Journal of dental research 2005. link 12 Ullbro C, Crossner CG, Nederfors T, Parhar R, Al Mohanna F, Meikle MC et al.. Cytokines, matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 in gingival crevicular fluid from patients with Papillon-Lefèvre syndrome. Acta odontologica Scandinavica 2004. link 13 Cury VF, Costa JE, Gomez RS, Boson WL, Loures CG, De ML. A novel mutation of the cathepsin C gene in Papillon-Lefèvre syndrome. Journal of periodontology 2002. link 14 Liu R, Cao C, Meng H, Tang Z. Leukocyte functions in 2 cases of Papillon-Lefèvre syndrome. Journal of clinical periodontology 2000. link